N/A N=150 IV Iron for the Anemia of Traumatic Critical Illness
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
Thalassemia Major
Primary: Change of Hematocrit Adjusted Volume of Red Blood Cells (RBC) — -5.934 % change of hematocrit-adjusted volume
Phase 2 N=100 Practical Anemia Bundle for SusTained Blood Recovery
Anemia · Critical Illness
Primary: Hemoglobin Concentrations — 11.5; 12.2 g/dL — p=0.02
N/A N=61 Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Phase 2 N=102 Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
N/A N=32 Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions
Thalassemia
Primary: Report of Pain by Age Group — 23; 61; 18; 51 percentage of participant-cycles — p=<.001
Phase 2 N=6 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs
Sickle Cell Disease · Thalassemia · Diamond-Blackfan Anemia
Primary: Count of Participants With Stable Engraftment Post Hematopoietic Cell Transplantation (HCT) — 3 Participants
Phase 3 N=102 Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Phase 3 N=147 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Phase 2 N=11 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
N/A N=62 Intelligent Control Approach to Anemia Management
End-Stage Renal Disease
Primary: Percent Hb 10-12 g/dL — 61.9; 72.5 Percent
Phase 3 N=51 Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia
Anemia · Iron Deficiency Anemia
Primary: Feasibility of Enrolling Patients in the Trial — 85 participants
Phase 3 N=3,506 Myocardial Ischemia and Transfusion
Myocardial Infarction · Anemia
Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
Phase 3 N=239 A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q
Anemia
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…
Phase 4 N=154 Clinical Evaluation of Iron Treatment Efficiency Among Non-anemic But Iron-deficient Female Blood Donors
Fatigue · Iron Deficiency
Primary: Level of Fatigue Before and After Iron Treatment/Placebo, Using a 10 Point Visual Analogue Scale. — 3.4; 3.5 centimeter — p=0.69
Phase 2 N=5 A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Transfusion Dependent Beta-thalassemia
Primary: Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion — 5; 2 participants
Phase 2 N=60 Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
Cardiac Iron Overload
Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio
Phase 3 N=1,683 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants
Phase 4 N=243 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
N/A N=62 Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
Myelodysplastic Syndromes
Primary: Number of Participants With Receipt of Second Transfusion
Phase 1 N=22 Biotin-RBC Transfusion in SCD
Sickle Cell Disease
Primary: Percentage of Biotin Labeled RBCs — 97.3; 80; 21 percentage of biotin-labeled RBCs
Phase 2 N=60 Transfusion Strategies in Pediatric Cardiothoracic Surgery
Congenital Heart Disease
Primary: Mean Arterial Lactate Level — 1.4; 1.4 mmol/L
Phase 4 N=88 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Ulcerative Colitis · Crohn's Disease
Primary: Mean Change in Haemoglobin Concentration. — 1.22; 1.30 g/dl — p=0.23
Phase 3 N=22 Stem Cell Transplant for Hemoglobinopathy
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Phase 4 N=38 Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial
Iron Deficiency Anemia of Pregnancy · Iron Malabsorption
Primary: Maternal Anemia at Delivery — 4; 11 Participants — p=0.039
Phase 3 N=267 Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
Primary Myelofibrosis · MPN-associated Myelofibrosis
Primary: Percentage of Participants Who Achieved RBC-Transfusion Independence — 17.3; 16.7 percentage of participants — p=1.000
N/A N=60 Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Efficacy of 1020 mg of Ferumoxytol Over 15 Minutes. Hemoglobin Measurements Will Take Place at Four and Eight Week Visit. — 85; 58; 92; 86 percentage of participants
Phase 2 N=184 Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
Anemia · Hemosiderosis
Primary: The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths — 85; 99; 36; 50 Participants
Phase 3 N=160 Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
Anemia
Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants